CN102370989B - Medicinal composition for treating urinary system diseases - Google Patents
Medicinal composition for treating urinary system diseases Download PDFInfo
- Publication number
- CN102370989B CN102370989B CN 201010261235 CN201010261235A CN102370989B CN 102370989 B CN102370989 B CN 102370989B CN 201010261235 CN201010261235 CN 201010261235 CN 201010261235 A CN201010261235 A CN 201010261235A CN 102370989 B CN102370989 B CN 102370989B
- Authority
- CN
- China
- Prior art keywords
- treatment
- carbon element
- medical component
- urinary system
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Abstract
The invention provides a medicinal composition for treating urinary system diseases. A carbon material of which the carbon content is over 60 percent by weight is loaded onto a water-containing carrier to form a pharmaceutically-acceptable water-containing carrier loaded with the carbon material; the unit dosage of the carbon material is between 0.1 mg/ml and 500 mg/ml; the diameter of the carbon material is between 2 nanometers and 2 millimeters; and the carbon material can be combined with metal particles such as silver, platinum, palladium, gold, zinc or copper and the like. The medicinal composition can be contacted with a bladder in an animal body and relevant tissues, has the effects of sterilizing and lowering cystitis, effectively controlling infection, prompting healing of a wound on the surface of the bladder, and relieving the symptoms of a patient suffering from cystitis.
Description
Technical field
The present invention is relevant with medical component, and it further is to make material with carbon element is stated from an aqueous carrier, makes both form the medicinal acceptable aqueous carrier that is loaded with material with carbon element and in order to treat the medical component of urinary system.
Background technology
Press, known common diseases of urinary system mostly is cystitis or urinary tract infection, this urinary system may be because antibacterial, chemicals, lonizing radiation, cancer therapy drug or infect institute by exogenous antibacterial and cause, also or can be because imposing medicine cause resistance to reduce consequently bacterial invasion causes, and its spy is apt to occur in the women or use the catheter patient, and its simplest determination methods is cystitis whether to occur determining whether producing by bacteriuria disease phenomenon, be that every milliliter of urine amount of bacteria is greater than 105CFU, wherein, it is 49% that the long-range 2 centimeters places of male urethra have the antibacterial sojourner to be about 98%, 5 centimeter place; And the ratio that its antibacterial of women lives away from home may be higher, therefore, has cystitis or pyelonephritis to produce when the urine amount of bacteria is too high; And can find with reference to the statistics of TaiWan, China intensive care unit nosocomial infection in 2007, urinary tract infection accounts for nosocomial infection 37.5% for maximum, no matter and be medical center or regional hospital, urinary tract infection is in first of TaiWan, China intensive care unit nosocomial infection, so the antibacterial in all age levels infects the diseases of urinary system that causes at present, as seen still is in first with urinary tract infection.Again, the treatment of the intrusive mood such as urinary catheterization or cystoscopy, it is the modal medical care precess of hospital, it also is the main cause of exogenous infection, because it can bring antibacterial into bladder, and might cause that up property antibacterial infects simultaneously, and then cause bacterial cystitis, severe patient to tend to cause acute cystitis or nephritis etc.; As, general modal bacterial cystitis, the place of its inflammation is to present the situations such as red, swollen, the congestion of blood vessel on the mucosa of bladder, and interstitial cystitis is to produce the inflammation phenomenon between the lower floor of mucosa and Musclar layer, therefore, when occuring, cystitis generally can cause bladder not accommodate pain, and the urgent relevant disease of pollakiuria, urine appears, and when treating cystitis not at that time, tend to because bladder produces serious infection, and the kidney that may make sufferer loses function, may need to wash later on kidney, even the danger of the septicemia died from is arranged.
And the therapy for the treatment of at present cystitis mainly contains drug therapy, the cystitis treatments methods such as antibiotic vesicoclysis or instillation administration, wherein, no matter be to utilize the instillation administration as monotherapy, perhaps with the conjoint therapy of instillation in conjunction with other therapy, perhaps with the sequential therapy of above-mentioned triplicity, its employed medicine, such as dimethyl sulfoxide, warexin (clorpactin), heparin, hyaluronic acid, amycin, chondroitin sulfate, sodium bicarbonate, silver nitrate, the many sodium sulfate of pentosan, sodium cromoglicate, penicillin, nitrofural, gentamycin or argyrol etc., polyphyly is take bladder mucosa and the stroma layer target as the treatment cystitis, make thus pain, the symptom of the cystitis such as uric acid and urgent micturition can obtain to alleviate, and the technology that prevention urinary tract antibacterial infects has the prevention of antibiotic method, catheter surface coating technology, argentiferous or silver-plated catheter technology etc.
Yet after using the said medicine treatment, although can kill a large amount of antibacterials, but also cause toxoid (Lipopolysaccharides, LPS) be the generation of ester poly candy body, and toxoid (LPS) stems from bacteria cell wall clinically, and can cause the bladder inflammation, induce simultaneously the bladder emiocytosis basic element of cell division (cytokine), comprise IL-1 α, β, TNF-α, IL-6, the inflammatory factor such as IL-8 and IL-10, inflammatory factor is also played the part of crucial role, impel the bladder leukocyte to assemble, cause red, swollen, heat, the inflammation phenomenon of pain, severe patient causes bleeding, above-mentioned phenomenon also is common in the person that carries the catheter for a long time, because can't avoiding exogenous antibacterial to infect, and cause the complexity infection problems, such as the chronic bladder inflammation etc., and some sufferer and meeting are because treatment is incomplete, and then the generation severe bacterial infections, even septicemia and death, only, in these cystitis therapies or the technology that infects of prevention urinary tract antibacterial, seldom can within the persistent period, produce mitigation, perhaps carry out long-term treatment and use this prevention technique, and during treating, can have some side effect simultaneously.
Yet, treatment for cystitis, if relying on merely antibacterial drug therapy infects, often fall flat, and due to illness suffer from often after antibacterial infects and produces amount reproduction, because produce red, swollen, hot, the pain after just seek medical advice, and delay treating time, also can cause the danger of the larger burden of health and increase resistance, this also is that the complexity antibacterial infects or antibiotic-resistant bacteria infects the main cause that cystitis is difficult to treat, and also can't repair at once to prevent that to bladder mucosa and stroma more antibacterials from entering; If antibacterial that can quick adsorption causes the bladder inflammation when the bladder inflammation, and remove the endotoxin material to the impact of human body, repair bladder mucosa and the stroma destroyed and prevent that antibacterial from entering and breeding, impel the bladder surfaces wound healing, more effectively infection control prevents from repeatedly showing effect, cystitis patient's disease is releived, its necessity is arranged in fact.
Summary of the invention
The object of the present invention is to provide a kind of medical component for the treatment of urinary system, to improve the defective that exists in the known technology.
For achieving the above object, the medical component for the treatment of urinary system provided by the invention, it mainly is that the material with carbon element of percentage by weight more than 60wt% with carbon content is stated from an aqueous carrier for this medical component, make both form the medicinal acceptable aqueous carrier that is loaded with material with carbon element, wherein, the diameter of this material with carbon element is between between the 2nm to 2mm;
This medical component that is loaded with the aqueous carrier of material with carbon element is contacted with bladder and linked groups thereof in the animal body by this material with carbon element, reduces the symptom of cystitis.
The medical component of described treatment urinary system, wherein this its per unit dosage of aqueous carrier that is loaded with material with carbon element comprises the above material with carbon element of 0.01mg/ml.
The medical component of described treatment urinary system, wherein this its material with carbon element concentration of aqueous carrier that is loaded with material with carbon element is between per unit dosage 0.1mg/ml to 500mg/ml.
The medical component of described treatment urinary system, wherein the percentage by weight of the carbon content of this material with carbon element is more than 80wt%.
The medical component of described treatment urinary system, wherein this material with carbon element is combined with a metallic particles, this metallic particles is selected from the metallic particles by silver, platinum, palladium, gold, zinc or copper one of them or its group that forms, and the diameter of this metallic particles is between between the 2nm to 2mm, and the percentage by weight that this metallic particles accounts for material with carbon element weight is below the 20wt%.
The medical component of described treatment urinary system, wherein to account for the percentage by weight of material with carbon element weight be below the 5wt% to this metallic particles.
The medical component of described treatment urinary system, wherein this material with carbon element is selected from by carbon fiber, activated carbon fiber, activated carbon, graphite, expanded graphite, CNT, nano carbon microsphere, coke ball or carbon black one of them or its and forms the material with carbon element of group.
The medical component of described treatment urinary system, wherein, the diameter of this material with carbon element is between between the 20nm to 2mm, and the carbon-coating planar, stacked thickness (Lc) of this material with carbon element is between between the 1nm to 1000mm.
The medical component of described treatment urinary system, wherein this aqueous carrier is selected from by buffer, antibiotic medicament and treatment cystitis medicament one of them or its ethnic group that forms.
The medical component of described treatment urinary system, wherein this antibiotic medicament is selected from the antibiotic medicine by Trimethoprim-sulfame-thoxazole (TMP-SMX), Trimethoprim (TMP), sulfame-thoxazole (SMX), fluoroquinolones, Ciprofloxacin, Ofloxacin, Cephalexin and tetracycline one of them or its combination.
The medical component of described treatment urinary system, wherein this treatment bladder medicament is selected from by dimethyl sulfoxide, oxychlorosene and receives the treatment cystitis medicament of (Clorpactin), heparin, hyaluronic acid, amycin, chondroitin sulfate, sodium bicarbonate, silver nitrate, the many sodium sulfate of pentosan, sodium cromoglicate, penicillin, nitrofural, gentamycin or argyrol one or a combination set of.
The medical component of described treatment urinary system, wherein the structure of this material with carbon element and specific surface area value (BET) are 20m
2/ g-4000m
2Between/the g.
The medical component of described treatment urinary system, wherein the structure of this material with carbon element and specific surface area value (BET) are 200m
2/ g-2000m
2Between/the g.
Advantage of the present invention is with can to reach effect as follows:
1, the medical component for the treatment of urinary system of the present invention, this material with carbon element is stated from an aqueous carrier, make both form the medicinal receivable aqueous carrier that is loaded with material with carbon element, and can be bladder mucosa and accept, and then the phenomenon that produces of the cystitis of releiving, the therapeutic effect that also has simultaneously the long time effect.
2, the medical component for the treatment of urinary system of the present invention wherein, is stated from an aqueous carrier, makes both form the medicinal receivable aqueous carrier that is loaded with material with carbon element, and it further can be repaired bladder mucosa and produce further therapeutic effect.
3, the medical component for the treatment of urinary system of the present invention, the metallic particles of this material with carbon element institute combination is selected from the metallic particles by silver, platinum, palladium, gold, zinc or copper one of them or its group that forms, and the diameter of this metallic particles is between between the 2nm to 2mm, by the metallic particles of material with carbon element combining nano level, and strengthen its sterilization and reduce the effect of the symptom of cystitis.
4, the medical component for the treatment of urinary system of the present invention, the structure that its contained material with carbon element tool is higher and specific surface area value, and good bio-compatibility, can initiatively adsorb antibacterial, make intravesical malignant bacteria amount fast reducing below 105CFU, and the harmful substances such as the extracellular toxin of absorption antibacterial and endotoxin (LPS), the inflammatory response of cystitis slowed down, and along with urine excretes, and reach preventive effect.
Description of drawings
Fig. 1 induces inflammatory agent content measuring and bladder weight comparison diagram in its each group rat urine of preferred embodiment of the present invention.
Fig. 2 is the bladder H ﹠amp of the normal rat of its M1-1 of preferred embodiment of the present invention (Normal) group; E stained figure, in blood vessel (Blood vessel is arranged, BV), consist of the epithelial cell (Epithelium of mucosa, Ep), muscular tissue (Muscle, M), connective tissue (Connective tissue, CT) and interstitial lamella (Lamina propria, Lp).
Fig. 3 is its bladder H ﹠amp after rat induces inflammatory agent to induce inflammation of its M1-2 of preferred embodiment of the present invention (LPS) group; E stained figure, and show the bladder surfaces of inflammation has occurred that leukocyte (White blood cells, WBC) is assembled, edema (Edema) and hemorrhage (Bleed) phenomenon.
Fig. 4 is the H ﹠amp of its M1-2 of Fig. 3 (LPS) group bladder mucosa below tissue; E stained figure, and show serious internal hemorrhage phenomenon.
Fig. 5 is its bladder H ﹠amp after the medical component of rat through inducing inflammatory agent to induce the bladder inflammation, reinject the aqueous carrier that is loaded with material with carbon element of its M1-3 of preferred embodiment of the present invention (LSP-ACF) group treated; E stained figure.
Fig. 6 is concentration and the bladder weight comparison diagram of PCT (PCT) in its each group rat blood serum of preferred embodiment of the present invention.
Fig. 7 is its bladder of normal rat H ﹠amp of its M2-1 of preferred embodiment of the present invention (Normal) group; E stained figure.
Fig. 8 is its M2-2 of preferred embodiment of the present invention (LPS) group its bladder H ﹠amp of inflammation after inducing inflammatory agent to induce the bladder inflammation; E stained figure, very serious edema phenomenon can be found in its figure left side.
Fig. 9 be its M2-3 of preferred embodiment of the present invention (LPS-ACF) group after inducing inflammatory agent to induce the bladder inflammation, after the medical component treatment of the aqueous carrier that is loaded with material with carbon element of reinjecting, its bladder H ﹠amp; E stained figure.
Figure 10 is the normal rat of second embodiment of the invention M3-1 (Normal) group, its bladder H ﹠amp; E stained figure.
Figure 11 is that second embodiment of the invention M3-2 (LPS) organizes after inducing inflammatory agent to induce the bladder inflammation its bladder H ﹠amp; E stained figure can see that in the figure left side leukocyte is assembled, internal hemorrhage.
After Figure 12 is the medical component treatment of second embodiment of the invention M4-3 (LPS-ACF) group through inducing inflammatory agent to induce the bladder inflammation, reinject the aqueous carrier that is loaded with material with carbon element, its bladder H ﹠amp; E stained figure.
The specific embodiment
The preferred embodiment of the medical component for the treatment of urinary system of the present invention, this be used for the treatment of urinary system medical component its mainly be that the material with carbon element of percentage by weight more than 60wt% with carbon content is stated from an aqueous carrier, make both form the medicinal acceptable aqueous carrier that is loaded with material with carbon element, and this material with carbon element system is selected from by carbon fiber, activated carbon fiber, activated carbon, graphite, expanded graphite, CNT, nano carbon microsphere, the material with carbon element of coke ball or carbon black one or its composition group wherein, and the diameter of this material with carbon element system is between between the 20nm to 2mm, its carbon-coating planar, stacked thickness (Lc) is between between the 1nm to 1000mm, and structure and specific surface area value (BET) are 20m
2/ g-4000m
2Between/the g, wherein, its material with carbon element of preferred embodiment of the present invention is activated carbon fiber powder or activated carbon, and the percentage by weight of its carbon content is more than 80wt%, and structure and specific surface area value (BET) are 200m
2/ g-3000m
2Between/the g, simultaneously, this aqueous carrier is to be selected from by buffer, antibiotic medicament and treatment cystitis medicament one of them or its ethnic group that forms, and this its per unit dosage of aqueous carrier that is loaded with material with carbon element comprises the above material with carbon element of 0.01mg/ml, wherein, this aqueous carrier that is loaded with material with carbon element is the material with carbon element that contains in the per unit dosage between 0.1mg/ml to 500mg/ml in the preferred embodiment of the present invention; In addition, its chief component of second embodiment of the invention is that preferred embodiment is identical with the effect that produces, so repeat no more, wherein, this material with carbon element is further combined with a metallic particles, this metallic particles is to be selected from by silver, platinum, palladium, gold, the granule metal of the group of zinc or copper one of them or its composition, and the diameter of this metallic particles is between between the 2nm to 2mm, and the percentage by weight that this metallic particles accounts for material with carbon element weight is below the 20wt%, the percentage by weight that its granule metal of this second embodiment accounts for material with carbon element weight is below the 5wt%, and this granule metal forms the medical component for the treatment of urinary system with being stated from aqueous carrier again after material with carbon element combines; In addition, the antibiotic medicament of this aqueous carrier is the antibiotic medicament that is selected from by Trimethoprim-sulfame-thoxazole (TMP-SMX), Trimethoprim (TMP), sulfame-thoxazole (SMX), fluoroquinolones, Ciprofloxacin, Ofloxacin, Cephalexin and tetracycline one or a combination set of; And the treatment cystitis medicament of this aqueous carrier is to be selected from by dimethyl sulfoxide, oxychlorosene to receive the treatment cystitis medicament of (Clorpactin), heparin, hyaluronic acid, amycin, chondroitin sulfate, sodium bicarbonate, silver nitrate, the many sodium sulfate of pentosan, sodium cromoglicate, penicillin, nitrofural, gentamycin or argyrol one or a combination set of.
Thus, the material with carbon element of this medical component or the material with carbon element of joining gold metal particles all can be contacted with bladder and the linked groups thereof in the animal body, in order to treatment and prevention cystitis, acute cystitis, chronic cystitis, hemorrhagic cystitis, bacterial cystitis, aerogenesis cystitis, interstitial cystitis, bladder or urethra have the patient of wound patient and urinary tract infection, while is infection control effectively, prevent that cystitis from showing effect repeatedly, and impel the bladder surfaces wound healing, cystitis patient's disease is releived.
By for the effect of further understanding structural feature of the present invention, application technology means and institute's expection and reaching, occupation mode of the present invention is narrated, believing be able to have more deep and concrete understanding to the present invention therefrom, as described below:
See also Fig. 1 to shown in Figure 5, the material with carbon element of this medical component is activated carbon fiber, it further is available from by (the TAIWAN CARBON TECHNOLOGY CO. of platform carbon Science and Technology Co., Ltd., LTD) produce and the activated carbon fiber of peddling, and through be ground to granule be 50 μ m to 100 μ m, the structure of its material with carbon element and specific surface area value are 200m
2/ g～2000m
2/ g, and the aqueous carrier of preferred embodiment of the present invention is buffer, and this buffer further is sterilized water, material with carbon element to be added on to fill in the buffer part stir and become the aqueous carrier that is loaded with material with carbon element, and the per unit dosage that is loaded with the aqueous carrier of material with carbon element contains the material with carbon element of 0.2mg/ml, and select three female Sprague-Dawley rats, its weight is about 290g, is grouped into respectively again:
(1) M1-1 (Normal): normal rat, inflammatory agent is not induced in injection, and does not induce the bladder inflammation.
(2) M1-2 (LPS): inflammatory agent is induced in injection, induces the bladder inflammation.
(3) M1-3 (LPS-ACF): inflammatory agent is induced in injection, induces the bladder inflammation, and the aqueous carrier with material with carbon element is injected into the intravesical treatment again.
And these rats are anaesthetized with potassamide acid esters (urethane) first before beginning experiment, confirm after rat has been anaesthetized it to be fixed on the soft board with adhesive tape, again with polyethylene tube (polyethylene tube, PE-50) carry out intraurethral cannula, after said procedure is finished, carry out again the following step:
First to two rats of M1-2 (LPS) group and M1-3 (LPS-ACF) group respectively from urethral injection protamine sulfate (Protamine sulfate, PS) enter the bladders of these rats, and cause first two its bladder mucosa of rat of M1-2 (LPS) group and M1-3 (LPS-ACF) group injured, inflammatory agent is induced in injection again, the inflammatory agent of inducing that preferred embodiment of the present invention is injected is the endotoxic ester poly candy body (Lipopolysaccharides of common name, LPS) reach the effect of inducing the injured inflammation of bladder, and cause these rat bladders to produce the generation of inflammation phenomenon, the injection protamine sulfate after 45 minutes, inject again normal saline solution (normal saline) and clean bladder, the control scope of damage prevents that protamine sulfate from further removing to hurt bladder interstitial lamella cell.
After cleaning bladder, injecting and inducing inflammatory agent is that endotoxin 750 E.U. also induce its bladder of these rats to produce inflammation phenomenon again, once this induces inflammatory agent to add up to twice in simultaneously per half an hour injection, clean bladder with normal saline solution (normal saline) more afterwards, through one hour, three rats were collected respectively for the first time urine.
Then the rat of M1-3 (LPS-ACF) group is injected this medical component, and after the aqueous carrier of this its material with carbon element of medical component is added on buffer, its per unit dose concentration is 4mg/20ml, rat to M1-2 (LPS) group is then only injected normal saline solution, and per half an hour injection once, need altogether injection four times, again through one hour, three rats are collected respectively for the second time urine, altogether through after 24 hours, regather the bladder of these three rats, for weighing and make this three groups of its bladder of rat H ﹠amp; The E pathological section that dyes.
Please consult again shown in Figure 1, analyze and collect in the urine for the first time, this M1-1 (Normal) thus group need not gather for matched group, and the rat of M1-2 (LPS) group its induce inflammatory agent up to 9.6EU/ml, what this M1-3 (LPS-ACF) organized induces inflammatory agent namely up to 36.0EU/ml; And after three hours, also analyze again in the collected urine second time, this M1-1 (Normal) group for matched group its to induce inflammatory agent be 1.0EU/ml, this M1-2 (LPS) organizes it and induces inflammatory agent then to be down to 1.8EU/ml, this M1-3 (LPS-ACF) group is after injection has the medical component of this aqueous carrier that is loaded with material with carbon element, it induces the content of inflammatory agent then to drop to 1.0EU/ml, through comparing respectively M1-1 (Normal) group, it induces three rats of M1-2 (LPS) group and M1-3 (LPS-ACF) group behind the result of inflammatory agent test as can be known, by M1-3 (LPS-ACF) group as can be known, M1-2 (LPS) group is after inflammatory agent is induced in injection, it induces inflammatory agent content at 9.6EU/ml in the urine for the first time, and induce inflammatory agent in the rat body behind the natural metabolism, in three hours for the second time in the urine its induce inflammatory agent still remaining 1.8EU/ml in the rat body; And the rat of M1-3 (LPS-ACF) group induces inflammatory agent to induce the bladder inflammation in injection, it induces inflammatory agent concentration up to 36.0EU/ml in first time urine, but behind the medical component through injecting this aqueous carrier that is loaded with material with carbon element, it induces inflammatory agent content to be down to 1.0EU/ml in second time urine, induce inflammatory agent content identical with M1-1 (Normal) matched group, the medicine group system that this expression is loaded with the aqueous carrier of material with carbon element makes the bladder generation therapeutic effect of inflammation of rat;
Please consult shown in Figure 1ly, the bladder weight of being measured by three rats can also be found out injection, and this is loaded with its therapeutic effect of medical component of the aqueous carrier of material with carbon element again; The rat of this M1-2 (LPS) group is 177.3mg in its bladder weight; And the rat of M1-3 (LPS-ACF) group is after injection induces inflammatory agent to induce the bladder inflammation, and treat through injecting this medical component that is loaded with the aqueous carrier of carbonaceous material, the bladder weight of rat after smelting is treated of this M1-3 (LPS-ACF) group is down to 134.8mg, and this this medical component that is loaded with the aqueous carrier of material with carbon element of expression injection has produced the edema effect that treatment causes because of cystitis.
In order further to understand the inner situation of rat bladder, see also shown in Figure 2ly, be its normal bladder H ﹠amp of rat of M1-1 (Normal) group; The E stained sees under normal circumstances that by knowing on Fig. 2 its bladder surfaces is seen very level and smooth bladder mucosa epithelial cell; See also shown in Figure 3ly, be the H ﹠amp of rat its bladder after inducing inflammatory agent to induce inflammation of M1-2 (LPS) group; The E stained, and the rat that can see M1-2 (LPS) group is gathered in the bladder interstitial lamella of mucosa below because the inflammation phenomenon causes leukocyte, consult simultaneously shown in Figure 4, its interior tissue of rat of this M1-2 (LPS) group can be observed very serious internal hemorrhage phenomenon, see also shown in Figure 5, the rat of organizing for M1-3 (LPS-ACF) is the endotaxin induction inflammation through inducing inflammatory agent, and the treatment of the medical component through injecting this aqueous carrier that is loaded with material with carbon element, the H ﹠amp of its bladder; The E stained is through the bladder mucosa tissue of this M1-3 (LPS-ACF) relatively, can find that with the bladder mucosa tissue of this M1-1 of Fig. 2 (Normal) group normal rat both are very similar, the phenomenon of not finding to have the serious inflammation of bladder such as leukocyte gathering, edema, internal hemorrhage of this M1-3 (LPS-ACF) group rat, therefore, this represents that this medical component that is loaded with the aqueous carrier of material with carbon element makes the bladder generation therapeutic effect of inflammation of rat.
See also Fig. 6 to shown in Figure 9, its main embodiment is identical with preferred embodiment of the present invention, so repeat no more, wherein, this embodiment mainly is the PCT (Procalcitonin that measures in the rat blood serum, PCT) content, and the concentration determination of the PCT content in the serum mainly is the leading indicator of judging serious bacterial infection and whole body inflammatory response, therefore, when PCT concentration rises, mainly be that its bladder inflammation phenomenon of expression is bacteroidal infection, septic shock or other Severe general antibacterial infect and cause the bladder inflammation.
Please consult shown in Figure 6ly, M2-1 (Normal) group is the normal rat of contrast again, and its PCT concentration is 0.021ng/ml; M2-2 (LPS) group is for through inducing inflammatory agent to induce the rat of inflammation, and its PCT concentration increases to 0.036ng/ml; And M2-3 (LPS-ACF) group is through inducing inflammatory agent to induce inflammation, and the rat behind injection for curing, its PCT concentration is 0.02ng/ml, PCT concentration through relatively finding M2-3 (LPS-ACF) group rat and M2-1 (Normal) group rat is suitable, and the bladder weight that compares simultaneously M2-2 (LPS) group rat is 177.6mg, after treatment, be down to 138.1mg with the bladder weight of M2-3 (LPS-ACF) group rat and can have found that this medical component that is loaded with the aqueous carrier of material with carbon element has curative effect really to the bladder inflammation.
Please consult again Fig. 7 to shown in Figure 9, be the H﹠amp of its bladder of rat of these different groups; The E histopathologic slide that dyes, please consult first the bladder body section that this M2-1 shown in Figure 7 (Normal) organizes its rat and can see very level and smooth bladder mucosa, and this M2-2 shown in Figure 8 (LPS) organizes the bladder body section of its rat and can see very serious edema phenomenon by left side among the figure; And this M2-3 shown in Figure 9 (LPS-ACF) organizes the bladder body section of its rat and can see and present level and smooth bladder mucosa surface, do not find simultaneously the serious inflammation phenomenons of bladder such as leukocyte gathering, edema and internal hemorrhage, therefore, represent that this medical component that is loaded with the aqueous carrier of material with carbon element makes the bladder generation therapeutic effect of inflammation of rat.
See also Figure 10 to shown in Figure 12, be the H ﹠amp of its bladder of rat of this difference group; The E histopathologic slide that dyes, its main embodiment is identical with preferred embodiment of the present invention, so repeat no more, wherein, the medical component in order to treat cystitis that M3-3 (LPS-ACF) group is injected is the second embodiment of the present invention, and its mainly be with metallic particles be stated from aqueous carrier again after this material with carbon element combines and be formed for treating the medical component of cystitis, and the selected metallic particles of second embodiment of the invention is nano level metal silver granule, please consults first its bladder of the normal rat H ﹠amp that Figure 10 shows that M3-1 (Normal) group; The E stained, can be seen without inflammation by Figure 10, without edema with without the condition of illness of internal hemorrhage, shown in Figure 11ly can see that M3-2 (LPS) group is after inducing inflammatory agent to induce the bladder inflammation and consult, can see obvious leukocyte among its figure assembles, the serious inflammation phenomenon of the bladder such as edema and internal hemorrhage, please consult again the rat that can see M4-3 (LPS-ACF) group shown in Figure 12, it is first through inducing inflammatory agent to induce inflammation, after the material with carbon element of metallic particles that contains silver by injection is again treated, can find that by Figure 12 leukocyte is not assembled, the serious inflammation phenomenon of the bladder such as edema and internal hemorrhage, therefore, this material with carbon element formed medical component that combines with the metallic particles of argentiferous has sterilization and reduces the effect of the symptom of cystitis.
The above only is of the present invention one better possible embodiments, so such as use the equivalent structure variation that the interest field of description of the present invention and application is done, ought to be included in the claim scope of the present invention.
Claims (20)
1. medical component for the treatment of urinary system, it mainly is material with carbon element to be added in the aqueous carrier fully stir for this medical component, make both form the medicinal acceptable aqueous carrier that is loaded with material with carbon element, wherein, the percentage by weight of carbon content is more than 60wt% in this material with carbon element, and the diameter of this material with carbon element is between between the 2nm to 2mm.
2. the medical component for the treatment of urinary system according to claim 1, wherein, this its per unit dosage of aqueous carrier that is loaded with material with carbon element comprises the above material with carbon element of 0.01mg/ml.
3. the medical component for the treatment of urinary system according to claim 2, wherein, this its material with carbon element concentration of aqueous carrier that is loaded with material with carbon element is between per unit dosage 0.1mg/ml to 500mg/ml.
4. the medical component for the treatment of urinary system according to claim 1, wherein, the percentage by weight of the carbon content of this material with carbon element is more than 80wt%.
5. the medical component for the treatment of urinary system according to claim 1, wherein, this material with carbon element is combined with a metallic particles, this metallic particles be selected from by silver, platinum, palladium, gold, zinc or copper wherein one or more, and the diameter of this metallic particles is between between the 2nm to 2mm, and the percentage by weight that this metallic particles accounts for material with carbon element weight is below the 20wt%.
6. the medical component for the treatment of urinary system according to claim 5, wherein, the percentage by weight that this metallic particles accounts for material with carbon element weight is below the 5wt%.
7. the medical component for the treatment of urinary system according to claim 1, wherein, this material with carbon element be selected from by carbon fiber, activated carbon fiber, activated carbon, graphite, expanded graphite, CNT, nano carbon microsphere, coke ball or carbon black wherein one or more.
8. the medical component for the treatment of urinary system according to claim 1, wherein, the diameter of this material with carbon element is between between the 20nm to 2mm, and the carbon-coating planar, stacked thickness of this material with carbon element is between between the 1nm to 1000mm.
9. the medical component for the treatment of urinary system according to claim 1, wherein, this aqueous carrier is selected from by buffer, antibiotic medicament and treatment cystitis medicament one of them or its ethnic group that forms.
10. the medical component for the treatment of urinary system according to claim 9, wherein, this antibiotic medicament is selected from the antibiotic medicine by first oxygen Benzyl Aminometradine-sulfamethoxazole, first oxygen Benzyl Aminometradine, sulfamethoxazole, fluoroquinolones, ciprofloxacin, ofloxacin, a spore ammonia Benzyl and tetracycline one of them or its combination.
11. the medical component for the treatment of urinary system according to claim 9, wherein, this treatment bladder medicament be selected from by dimethyl sulfoxide, oxychlorosene receive, the treatment cystitis medicament of heparin, hyaluronic acid, amycin, chondroitin sulfate, sodium bicarbonate, silver nitrate, the many sodium sulfate of pentosan, sodium cromoglicate, penicillin, nitrofural, gentamycin or argyrol one or a combination set of.
12. the medical component for the treatment of urinary system according to claim 1, wherein, the specific surface area value of this material with carbon element is 20m
2/ g-4000m
2Between/the g.
13. the medical component for the treatment of urinary system according to claim 12, wherein, the specific surface area value of this material with carbon element is 200m
2/ g-2000m
2Between/the g.
14. medical component for the treatment of urinary system, this medical component mainly is material with carbon element to be added in the aqueous carrier fully stir, make both form the medicinal acceptable aqueous carrier that is loaded with material with carbon element, the percentage by weight of carbon content is more than 60wt% in this material with carbon element, in this carbonaceous material and contain metallic particles, the percentage by weight that this metallic particles accounts for this aqueous carrier that is loaded with material with carbon element is below the 20wt%, wherein, and this material with carbon element is selected from by carbon fiber, activated carbon fiber, activated carbon, graphite, expanded graphite, CNT, nano carbon microsphere, coke ball or carbon black wherein one or more, and the diameter of this material with carbon element is between between the 2nm to 2mm.
15. the medical component for the treatment of urinary system according to claim 14, wherein, the percentage by weight of this its carbon content of material with carbon element is more than 80wt%, and the metallic particles of institute's combination is selected from by silver, platinum, palladium, gold, zinc or wherein one or more of copper, and the diameter of this metallic particles is below the 5wt% between between the 5nm to 2mm and this metallic particles accounts for the percentage by weight of material with carbon element weight.
16. the medical component for the treatment of urinary system according to claim 14, wherein, this its per unit dosage of aqueous carrier that is loaded with material with carbon element includes between the material with carbon element between 0.1mg/ml to 500mg/ml.
17. the medical component for the treatment of urinary system according to claim 14, wherein, the specific surface area value of this material with carbon element is 200m
2/ g-2000m
2Between/the g.
18. the medical component for the treatment of urinary system according to claim 14, wherein, this aqueous carrier is selected from by buffer, antibiotic medicament and treatment cystitis medicament one of them or its ethnic group that forms.
19. the medical component for the treatment of urinary system according to claim 18, wherein, this antibiotic medicine is selected from the antibiotic medicine by Jia Yang Benzyl Aminometradine-sulfamethoxazole, Jia Yang Benzyl Aminometradine, sulfamethoxazole, fluoroquinolones, ciprofloxacin, ofloxacin, Tou Bao An Benzyl and tetracycline one of them or its combination.
20. the medical component for the treatment of urinary system according to claim 18, wherein, this treatment bladder medicine be selected from by dimethyl sulfoxide, oxychlorosene receive, the treatment cystitis medicine of heparin, hyaluronic acid, amycin, chondroitin sulfate, sodium bicarbonate, silver nitrate, the many sodium sulfate of pentosan, sodium cromoglicate, penicillin, nitrofural, gentamycin or argyrol one or a combination set of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010261235 CN102370989B (en) | 2010-08-19 | 2010-08-19 | Medicinal composition for treating urinary system diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010261235 CN102370989B (en) | 2010-08-19 | 2010-08-19 | Medicinal composition for treating urinary system diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102370989A CN102370989A (en) | 2012-03-14 |
| CN102370989B true CN102370989B (en) | 2013-05-29 |
Family
ID=45790570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010261235 Active CN102370989B (en) | 2010-08-19 | 2010-08-19 | Medicinal composition for treating urinary system diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102370989B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102960366A (en) * | 2012-12-05 | 2013-03-13 | 太原理工大学 | Preparation method of Ag-carrying carbon microsphere antibacterial agent |
| CN103316043B (en) * | 2013-06-07 | 2015-10-28 | 逢甲大学 | Containing the medicinal usage of the compositions of carbonaceous material and active particle |
| CN103316044B (en) * | 2013-06-07 | 2015-11-04 | 逢甲大学 | For suppressing the compositions structure of intestines and stomach bacteriological infection |
| TWI634891B (en) * | 2017-08-17 | 2018-09-11 | 逢甲大學 | Medicine for treating or preventing colorectal cancer |
| CN107281492B (en) * | 2017-08-17 | 2021-09-24 | 柯泽豪 | Application of composition |
| KR102385760B1 (en) * | 2019-04-26 | 2022-04-11 | 티씨엠 바이오테크 인터내셔널 코포레이션 | Pharmaceutical composition for the prevention of recurrent urinary tract infection |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548367A (en) * | 2003-05-16 | 2004-11-24 | 中国人民解放军军事医学科学院毒物药 | Nano level active carbon and its prepn and use |
| CN1634588A (en) * | 2004-12-13 | 2005-07-06 | 杨维稼 | Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer |
| CN1686165A (en) * | 2005-05-13 | 2005-10-26 | 杨维稼 | Medical nano-carbon tube composition, preparation method and its application |
-
2010
- 2010-08-19 CN CN 201010261235 patent/CN102370989B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1548367A (en) * | 2003-05-16 | 2004-11-24 | 中国人民解放军军事医学科学院毒物药 | Nano level active carbon and its prepn and use |
| CN1634588A (en) * | 2004-12-13 | 2005-07-06 | 杨维稼 | Medicinal nano carbon microsphere and its application for preparing medicine to treat cancer |
| CN1686165A (en) * | 2005-05-13 | 2005-10-26 | 杨维稼 | Medical nano-carbon tube composition, preparation method and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102370989A (en) | 2012-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102370989B (en) | Medicinal composition for treating urinary system diseases | |
| Da Costa et al. | Randomized, double‐blind, placebo‐controlled, dose‐ranging study of granulocyte‐macrophage colony stimulating factor in patients with chronic venous leg ulcers | |
| Bertl et al. | The effect of local and systemic statin use as an adjunct to non-surgical and surgical periodontal therapy—A systematic review and meta-analysis | |
| US20050238733A1 (en) | Topical anesthesia of the urinary bladder | |
| DeClue et al. | Effects of subanesthetic doses of ketamine on hemodynamic and immunologic variables in dogs with experimentally induced endotoxemia | |
| Oottamasathien et al. | A murine model of inflammatory bladder disease: cathelicidin peptide induced bladder inflammation and treatment with sulfated polysaccharides | |
| Bayram et al. | The effects of intraoperative infusion of dexmedetomidine on early renal function after percutaneous nephrolithotomy | |
| KR20140107190A (en) | Use of glutaryl histamine to treat respiratory tract infections | |
| Corsetti et al. | Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation | |
| Tang et al. | Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial | |
| Nichols et al. | Phrenic long-term facilitation following intrapleural CTB-SAP-induced respiratory motor neuron death | |
| Li et al. | Houttuynia cordata extract ameliorates bladder damage and improves bladder symptoms via anti-inflammatory effect in rats with interstitial cystitis | |
| DE69916643T2 (en) | USE OF HYALURONIC ACID FOR TREATMENT OF IRRADIATED BLOWN IGNITION | |
| Kumar Shrestha et al. | Uropathogenic Escherichia coli in urinary tract infections: A review on epidemiology, pathogenesis, clinical manifestation, diagnosis, treatments and prevention | |
| US9132151B2 (en) | Method for treating urinary system disorders | |
| Yang et al. | Role of bladder hydrodistention and intravesical sodium hyaluronate in the treatment of interstitial cystitis | |
| Yoshino et al. | Wound, pressure ulcer and burn guidelines–6: Guidelines for the management of burns | |
| Karsenty et al. | Efficacy of interstitial cystitis treatments: a review | |
| US20220184226A1 (en) | Complexes and methods of reducing inflammation | |
| US9011881B2 (en) | Pharmaceutical composition for treating urinary system disorders | |
| TWI474818B (en) | Treatment of urinary system of medical composition | |
| JP2012116818A (en) | Pharmaceutical composition for treatment of urinary system disease | |
| Reid et al. | Bacterial biofilm formation on the bladder epithelium of spinal cord injured patients. II. Toxic outcome on cell viability | |
| GB2486713A (en) | Pharmaceutical composition for treating urinary system disorders | |
| CN113710254B (en) | Pharmaceutical composition for preventing recurrent urinary tract infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |